Reading between the lines of the recent Alzheimer’s Research summary article, what the Budget does not say is at least as significant as what it does! It talks in generalities about investment in £6.1 billion for medical research, including clinical trials, but does not give any specifics about how this will benefit dementia researchers. The overlying Industrial Strategy does identify life sciences as a ‘key growth sector’ but this is merely stating the obvious for a sector in which Britain has been a leader for the better part of a century. It should be the work of minutes rather than months to work out that dementia should be a prime target, as one of the largest and certainly most poorly served sectors for effective pharmaceutical therapies. Much of the current plan seems to be taken up with essentially palliative steps in clinical diagnosis and disease prevention, rather than the pharmaceutical means of preventing, delaying or curing the condition. Verdict: Vagueness 8, Disappointment 10.
Dementia research deserves more than vague promises and broad generalities—it demands action. The Autumn Budget leaves critical questions unanswered, and those affected by dementia can’t afford to wait. Let’s push for clarity, urgency and targeted funding for life-changing therapies. If you’re passionate about making a difference, contact me at 07549669496 or message me through Neuroform Education. Together we can advocate for real progress.
Comments